GlassScriptPhysician profile
Amber Barker
NPI 1649763046
$3,196.44
in general payments reported to CMS, 2019-2025
28 companies · $662 in 2025
The $662 reported for 2025 was more than what a typical Psychiatric/Mental Health (Nurse Practitioner) provider received nationally (typical 2025 total: $257).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $387 · 2022: $701 · 2023: $712 · 2024: $735 · 2025: $662.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,109.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,108.56 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Otsuka America Pharmaceutical, INC. | $471.83 | 2021-2025 | Rexulti |
| Abbvie INC. | $447.32 | 2021-2025 | |
| Ironshore Pharmaceuticals INC. | $419.99 | 2022-2024 | Jornay Pm |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $290.34 | 2021-2025 | Caplyta |
| Vanda Pharmaceuticals INC. | $220.38 | 2024-2025 | Fanapt |
| Sunovion Pharmaceuticals INC. | $189.83 | 2021-2022 | |
| Takeda Pharmaceuticals U.S.A., INC. | $150.61 | 2022-2025 | Trintellix |
| Novo Nordisk INC | $108.23 | 2023-2025 | Rybelsus, Ozempic |
| Supernus Pharmaceuticals, INC. | $100.39 | 2023-2024 | Qelbree, Qelbree |
| Corium, LLC | $81.05 | 2022-2023 | Azstarys |
| Alkermes, INC. | $79.07 | 2023-2024 | Lybalvi |
| Collegium Pharmaceutical, INC. | $73.51 | 2025 | Jornay Pm |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $66.48 | 2021-2023 | Xifaxan |
| Novartis Pharmaceuticals Corporation | $59.93 | 2023-2024 | |
| Axsome Therapeutics, INC. | $58.13 | 2022-2024 | Auvelity |
Show all 28 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Bayer Healthcare Pharmaceuticals INC. | $57.89 | 2023-2025 | |
| Mylan Specialty L.P. | $51.51 | 2022-2024 | Yupelri |
| Lundbeck LLC | $45.64 | 2022-2024 | Rexulti |
| Idorsia Pharmaceuticals US INC | $40.84 | 2023 | Quviviq |
| Astrazeneca Pharmaceuticals LP | $39.56 | 2025 | Breztri |
| Sumitomo Pharma America, INC. | $24.33 | 2023 | Gemtesa |
| Viatris Specialty LLC | $21.43 | 2025 | Yupelri |
| Almatica Pharma LLC | $20.16 | 2025 | Loreev Xr |
| Shield Therapeutics INC | $18.06 | 2023 | |
| Neurocrine Biosciences, INC. | $16.70 | 2021 | |
| E.R. Squibb & Sons, L.L.C. | $16.26 | 2025 | Cobenfy |
| Biohaven Pharmaceutical Holding Company LTD. | $13.94 | 2022 | |
| Grifols USA, LLC | $13.03 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Amber Barker listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.